Literature DB >> 6416185

In vitro assessment of combined antibiotic and mucolytic treatment for Pseudomonas aeruginosa infection in cystic fibrosis.

D P Heaf, G J Webb, D J Matthew.   

Abstract

The minimal inhibitory concentration of azlocillin for Pseudomonas aeruginosa is appreciably reduced when combined with the mucolytic agent mesna (Mistabron) because of an independent bacteriostatic effect of mesna. Bactericidal activity of azlocillin is unaltered by mesna. Mesna inhalations alone or combined with azlocillin may benefit cystic fibrosis patients with pseudomonas lung infections.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6416185      PMCID： PMC1628280          DOI： 10.1136/adc.58.10.824

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN： 0003-9888            Impact factor:   3.791


  5 in total

1.  N.A.C. AND ANTIBIOTICS IN CYSTIC FIBROSIS.

Authors:  D LAWSON; B A SAGGERS
Journal:  Br Med J       Date:  1965-01-30

2.  The effect of N-acetylcysteine on the viscosity of tracheobronchial secretions in cystic fibrosis of the pancreas.

Authors:  H W REAS
Journal:  J Pediatr       Date:  1963-01       Impact factor: 4.406

3.  Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis.

Authors:  M E Hodson; A R Penketh; J C Batten
Journal:  Lancet       Date:  1981-11-21       Impact factor: 79.321

4.  Outer membrane of Pseudomonas aeruginosa: heat- 2-mercaptoethanol-modifiable proteins.

Authors:  R E Hancock; A M Carey
Journal:  J Bacteriol       Date:  1979-12       Impact factor: 3.490

5.  Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis.

Authors:  P H Weller; D Ingram; M A Preece; D J Matthew
Journal:  Thorax       Date:  1980-01       Impact factor: 9.139
  5 in total
  4 in total

1.  Influence of erdosteine, a mucolytic agent, on amoxycillin penetration into sputum in patients with an infective exacerbation of chronic bronchitis.

Authors:  G Ricevuti; A Mazzone; E Uccelli; G Gazzani; G B Fregnan
Journal:  Thorax       Date:  1988-08       Impact factor: 9.139

2.  Management of the chest in cystic fibrosis.

Authors:  R Dinwiddie
Journal:  J R Soc Med       Date:  1986       Impact factor: 5.344

Review 3.  Management of the chest in cystic fibrosis.

Authors:  B M Phillips; T J David
Journal:  J R Soc Med       Date:  1987       Impact factor: 5.344

Review 4.  Exercise-associated prevention of adult cardiovascular disease in children and adolescents: monocytes, molecular mechanisms, and a call for discovery.

Authors:  Dan M Cooper; Shlomit Radom-Aizik
Journal:  Pediatr Res       Date:  2019-10-24       Impact factor: 3.756
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.